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Abstract
Nucleic acids are the backbone of antisense therapy. Antisense oligonucleotide-
based therapeutics involves downregulation of gene expression. RNA-based drugs 
that include antisense oligonucleotides bear great therapeutic potential toward 
treatment of various diseases by altering RNA and/or reducing, restoring, and mod-
ifying protein expression through multiple molecular mechanisms. Pharmacology 
of targeted antisense therapy has provided the platform to translate its utility to the 
clinic.  Over the years, chemical modifications of antisense oligonucleotides have 
not only enhanced the specificity and efficacy but also reduced the side effects.   
These have changed the whole clinical trial design and provide newer strategies 
for therapies. Improvement in antisense oligonucleotide therapy technology has 
allowed and brought research from bench to clinic. Additionally, the use of small 
interfering RNAs, micro RNAs, ribozymes, and other antisense compounds toward 
the treatment of deadly diseases like cancers have demonstrated both preclinical 
and clinical responses. Furthermore, antisense therapy has great potential to target 
specific genes of interest in the context of precision medicine. Optimization of 
enhanced delivery, specificity, affinity, and nuclease resistance with reduced toxic-
ity is underway in different disease context. This chapter gives a complete overview 
of antisense therapy and highlights its potential. Here, we focused on the advances 
of the antisense technology, pharmacology, therapeutics, and drug discovery.
Keywords: antisense oligonucleotides, antisense therapy, antisense drug, 
antisense therapeutic, gene therapy
1. Introduction: antisense technology
The advancement in the next-generation sequencing enables us to identify the 
genetic heritages of several diseases, such as cancer, Parkinson’s, rheumatoid arthri-
tis, and Alzheimer’s, which brings to attention the development of personalized 
medicine [1]. This knowledge has been well adapted and accepted for diagnosis, 
but the field still lags toward pharmaceutical interventions to address the genetic 
defects underlying diseases. At present, small molecules and proteins are the two 
major classes of US Food and Drug Administration (FDA)-approved drugs [2]. 
Small-molecule drugs inhibit target proteins through competitive binding, whereas 
protein-based drugs (such as antibodies) can bind with high specificity to several 
targets. The size and stability of proteins are the major limitations of their utility 
for majority of disease targets [2], and both protein and small-molecule drugs 
cannot target every disease-relevant protein or gene. Thus, there is a current need 
to develop the drugs for personalized genomics. The mRNA- and DNA-based drugs 
are therapeutically more promising and have the great potential to cure the genetic 
defect [1]. The RNA-based drugs have emerged as a promising candidate to treat 
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diseases at the genetic (gene and RNA) levels. The delivery of therapeutic RNA has 
been limited due to several numbers of factors such as nucleic acid design, deliv-
ery methods, and materials for transport of RNA drugs to the site of  interest [1]. 
The current advancement in RNA and RNA-protein therapy has shown the great 
potential for the development of RNA delivery, and the clinical applications of 
RNA-based drugs have been proven by modulating gene/protein expression and 
gene editing [1].
An approach to fight disease by utilizing short DNA-like molecules is known as 
antisense oligonucleotides. This is the most effective and commonly used technol-
ogy to regulate the gene expression and drugs for targeted gene therapy. These 
antisense oligonucleotides bind to messenger RNA (mRNA) and impair the protein 
production and inhibit the gene expression. The antisense molecules are synthetic 
replica of specific mRNA sequence to block the function of the specific target gene 
of interest in the human genome. Recently, antisense therapy has emerged as a 
promising tool to treat various diseases, and for treatment, several antisense drugs 
have been approved by the FDA. For antisense gene therapy, chemically engineered 
oligonucleotides complementary to specific mRNA are inserted into the cells which 
stop the translation of the specific protein. Similarly, the antisense drug contains 
the vital molecule—“the noncoding mRNA”—which blocks the translation of a 
specific protein. The antisense oligonucleotides could be very useful to treat the 
viral diseases, genetic/hereditary diseases, as well as cancers. The naturally occur-
ring oligonucleotides bear poor stability and very low specificity and have a lot 
of side effects in vivo. The therapeutic use of oligonucleotides can be achieved 
by enhancing the stability and specificity of the molecules and reducing the side 
effects by chemical modification. The most common therapeutic oligonucleotides 
are small interfering RNA, ribozyme, DNAzyme, anti-gene, CpG, decoy, and 
aptamer. The chemical modification of antisense oligonucleotides can improve their 
ability to enter the cells to bind the specific target gene sequences which further 
disrupt the targeted gene function. Several antisense RNA and antisense oligonucle-
otide delivery systems such as virus vectors (retrovirus, adenovirus, and adeno-
associated virus) and liposomes have been developed to carry the antisense RNA or 
oligonucleotides through the cell membrane into the cytoplasm and nucleus. The 
oligonucleotides mainly target the ribonucleic acid (RNA), whereas small molecules 
and antibodies primarily target proteins due to their chemical properties and 
distinct molecular mechanism of action. The mRNA codes for protein to noncoding 
RNAs (such as microRNA, transfer RNA, small interfering RNAs, ribosomal RNA, 
and long noncoding RNAs). The main function of noncoding RNAs is the transfer 
of genetic information from DNA to protein [3]. The major therapeutic approach to 
target RNA-based therapy is antisense oligonucleotides because of their high affin-
ity, selectivity, ease of chemical modifications, and less toxicity. This chapter will 
provide a comprehensive overview of antisense therapy and their major therapeutic 
approaches.
The remarkable progress in the field of gene therapy and antisense therapy is 
apparent from numerous gene therapy- and antisense therapy-based clinical trials 
that are currently underway worldwide.
Gendicine (Ad-p53), the first gene therapy-based product, was approved in 
China for the treatment of head and neck squamous cell carcinoma in conjunction 
with radiotherapy. One AON drug, Vitravene, had been also approved for the local 
treatment of cytomegalovirus-induced retinitis, and several others are in clini-
cal trials, including those siRNAs, miRNAs, and ribozymes that are targeting the 
mRNA of different oncogenes and other cancer-promoting genes.
Although the application of gene therapy and antisense therapy to mediate tumor 
regression is well demonstrated in experimental and clinical settings, impediment 
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remains when translating this into large clinical application. The main obstacles 
that remained in cancer gene therapy and antisense therapy are the lack of delivery 
systems that successfully deliver an efficacious dose of a therapeutic gene (s) or 
antisense drug(s) to the targeted tumor site. Targeted gene or antisense drug delivery 
to distant tumors for therapeutic approaches is a demanding task that urges the 
development of delivery vectors capable of overcoming many barriers. Many scien-
tists have used viral and non-viral vectors to deliver the therapeutic gene or antisense 
compound in to the targeted tumor cells or tissues. Although the results of early gene 
therapy- and antisense therapy-based clinical trials using either viral or non-viral 
vectors have been encouraging, still it is difficult to find a single method that meets 
all the conditions for an ideal gene transfer and vector expression.
Limitations of the present vector technologies have slowed the progress of gene 
therapy and antisense therapy for cancer to the clinic. Thus, the development of 
appropriate delivery systems for targeting therapeutic genes and antisense agents 
into targeted tumor cells and tissues is one of the potential approaches that have to 
be further explored in the future in order to augment gene therapy and antisense 
therapy against a wide range of cancers. It is hoped that the next generation of carri-
ers could be a promising technology for systemic cancer gene therapy and antisense 
therapy.
2. Pharmacology of antisense drugs
The antisense oligonucleotides have the potential to manipulate the gene 
expression which prompted the field toward the therapeutic application and value 
of oligonucleotides as potential drugs and their targets [4]. The direct route to 
target RNA in a selective way is a well-established platform for drug discovery. 
The well-defined mechanisms, uncomplicated and easy to design, bring antisense 
oligonucleotides as a promising candidate for therapeutic development. The thera-
peutic potential of antisense drugs for the treatment of several diseases is already 
translated from bench to bedside, and many antisense drugs have entered into 
clinical trials for the treatment. The first patent on antisense therapy was granted 
to Molecular Biosystems company in 1991 for developing the antisense compounds. 
The first FDA-approved antisense product drug was afovirsen developed by Ionis 
Pharmaceuticals in 1992 which was a phosphorothioate oligonucleotide that 
targeted mRNA sequence of the E2 gene, which is associated with human papil-
lomavirus transcription and replication. Later oblimersen, a phosphorothioate 
oligonucleotide, was designed to target the Bcl-2 protein for the treatment of 
melanoma and certain leukemias. Unfortunately, both the drugs failed in the clini-
cal trial programs due to lack of efficacy and failure to demonstrate overall survival 
benefits and dose-limiting toxicity. Currently, several gene therapy- and antisense 
therapy-based clinical trials are ongoing. The major challenge of antisense drugs is 
effective and safe delivery to the target. The advancement toward antisense-based 
drug delivery is in progress. Several chemical modifications, novel chemistries, bet-
ter formulation, and design of oligonucleotide not only have improved the potency 
and tolerability of antisense drug but also have enhanced the drug distribution to 
the targeted RNA inside the cells [5, 6]. The clinical application of antisense drugs 
requires safe and efficient carrier system, and currently, the viral and non-viral vec-
tors are the most common methods used to deliver the antisense drugs specifically 
to the target tissues and cells. The viral vector-based delivery is most advantageous 
due to their high transfection efficiency [7]. Also, the new chemistries and better 
antisense oligonucleotide designs further improve the unwanted side effects, safety, 
and tolerability. From the last three decades, several antisense drugs have entered 
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into clinical trials and market for the treatment of a broad variety of diseases, and 
numerous oligonucleotides are under clinical development [6, 8–10]. The first-
generation antisense drug, fomivirsen, targeting cytomegalovirus, was approved 
for the treatment of cytomegalovirus retinitis [11]. Many second-generation drugs 
are under development and are showing encouraging activity in the clinic. Now 
oligonucleotide therapy has come a long way and has been established as promising 
therapeutic tool. During this period, several clinical trials have been performed on 
thousands of participants for several diseases and only six molecules provided the 
clear clinical benefit in rigorously controlled trials [10]. As of now, there are six 
FDA-approved drugs based on oligonucleotide therapy: (1) fomivirsen for treat-
ment of CMV retinitis in AIDS patients, (2) mipomersen for treatment of familial 
hypercholesterolemia, (3) defibrotide for treatment of veno-occlusive disease in 
the liver, (4) eteplirsen for the treatment of Duchenne muscular dystrophy, (5) 
pegaptanib for the treatment of neovascular age-related macular degeneration, and 
(6) nusinersen for the management of spinal muscular atrophy [10, 12]. In conclu-
sion oligonucleotide-based antisense therapy has provided solutions to untreatable 
diseases. Future inventions in this technology will help in establishing the better 
and affordable cure to many more diseases.
3. Antisense therapeutic interventions in various diseases
The antisense technology is well placed to influence the developments in human 
genetics and genomics to generate drugs for the treatment of monogenic and 
polygenic diseases. The “antisense” are the oligodeoxyribonucleotide molecules 
complementary to the DNA or RNA sequence of the target gene designed to hybrid-
ize specific mRNA. By capitalizing “antisense” DNA approach, the overexpressed 
proteins can be blocked in several diseases such as cancer, neurological diseases, 
cardiovascular diseases, inflammation and autoimmune diseases, infectious 
diseases, etc. [6].
3.1 Antisense therapy for cancer
The beauty of antisense technology is that it can precisely recognize the DNA 
location in a gene, a single mRNA class, and can distinguish between the normal 
and mutated oncogenes in cancer cells. Several studies have confirmed that in can-
cer patients, this can be used as an inhibitor of gene expression, which will decrease 
the tumor growth by manipulating the important cellular functions and protein 
production. By decreasing the specific gene expression, inducing the degradation 
of target mRNA, and initiating the premature termination of transcription, the 
antisense therapy can correct the abnormal expression of cellular genes and muta-
tions in tumor cells. One of the major limitations of this approach is nuclease deg-
radation. For this, several strategies are under development. Delivery of antisense 
oligo or drug to distant as well target tumors is a major hurdle. The development of 
suitable delivery systems for targeting therapeutic genes and antisense agents into 
targeted tumor cells and tissues is one of the potential approaches that needs to be 
further developed and explored. In order to enhance the gene therapy and antisense 
therapy against a wide variety of cancers and cancer types in future, the develop-
ment of next generation of carriers will a remarkable progress in the field of gene 
therapy and could serve as a promising technology for systemic cancer gene therapy 
and antisense therapy. As we know, cancer has been a major area of therapeutic 
investigation for antisense technology. Currently, custirsen, a chimeric 2′MOE-
modified antisense drug targeting clusterin, is being evaluated in phase III clinical 
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trials for the treatment of prostate and lung cancers [13]. Also, the antisense drug, 
AZD9150, which targets signal transducer and activates the transcription 3 (STAT3) 
in several types of cancers [14] has shown encouraging activity as a single agent in 
several cancer types. The modified oligonucleotide targeting androgen receptor is in 
the clinical trial as a possible treatment for prostate cancer [15]. Several additional 
antisense drugs, including microRNAs and siRNAs, are in early-stage clinical trials.
3.2 Antisense therapy for cardiovascular diseases
The first antisense drug, mipomersen, is approved by the FDA as an adjunct 
therapy for homozygous familial hypercholesterolemia, which reduces apolipopro-
tein B mRNA levels [16]. Apolipoprotein C III (apoCIII) plays a critical role in the 
metabolism of triglyceride-rich lipoproteins, and decreased expression is associated 
with a lower risk of cardiovascular disease [16, 17]. The clinical trial of volane-
sorsen, an antisense drug, is designed to reduce apoCIII mRNA levels, and the drug 
is currently being investigated in placebo-controlled phase III clinical trials for the 
treatment of familial chylomicronemia syndrome and familial partial lipodystro-
phy. It has been shown that severe factor XI deficiency provides protection against 
deep vein thrombosis and therefore cardiovascular morbidity and mortality [6]. 
The antisense drug IONIS-FXIRx can lower the factor XI levels and has the poten-
tial to be more effective than conventional anti-thrombotics. A phase II study with 
IONIS-FXIRx/BAY 2306001 is ongoing to investigate the drug’s effects in patients 
with end-stage renal disease on hemodialysis [6, 18, 19].
3.3 Antisense therapy for inflammation and autoimmune diseases
The antisense drugs have been and are currently being evaluated for multiple 
inflammatory diseases, such as inflammatory bowel disease. The oral drug, mon-
gersen targeting the SMAD7 mRNA, showed the promising effects on patients with 
ulcerative colitis. Also, alicaforsen drug, targeting intercellular adhesion molecule 1 
(CD54), has been tested for its effects by systemic delivery in patients with Crohn’s 
disease [20] as well as in the rectal enema patients with ulcerative colitis (or active 
unremitting pouchitis) [21–23]. This drug is currently being developed for the 
treatment of chronic refractory pouchitis [21, 24].
3.4 Antisense therapy in neurological disorders
Antisense drugs are being evaluated for multiple neurological diseases and are 
administered systemically into the cerebrospinal fluid (CSF) that surrounds the 
brain. Antisense oligonucleotides cannot cross the intact blood–brain barrier effi-
ciently; therefore, they are directly introduced into the CSF or parenchyma to treat 
brain or spinal cord diseases. Thus, neurological diseases can be approached using 
different antisense mechanisms and oligonucleotide designs, with single-stranded 
antisense oligonucleotides and siRNAs used for local therapy [6]. Duchenne 
muscular dystrophy is a progressive, severely disabling, and ultimately lethal 
neuromuscular disease caused by point mutations, insertions, or chromosomal 
rearrangements in the dystrophin gene resulting in truncated protein or loss of 
transcript through nonsense-mediated decay [25]. Because of multiple genomic 
alterations in Duchenne muscular dystrophy, no single oligonucleotide will address 
all forms of the disease [6, 25]. Antisense oligonucleotides designed to promote 
skipping of exon 51 are the most advanced in clinical trials, and the modified 
phosphorothioate oligonucleotide drug, eteplirsen, is under regulatory review for 
marketing approval. Additional antisense drugs are currently under development 
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for targeting other exons, which will broaden the treatment of the patient popula-
tion. Myotonic dystrophy type 1 (DM1) is a multisystemic disease caused by a 
triplet repeat expansion (CTG) in the 3′ untranslated region of myotonic dystrophy 
protein kinase (DMPK) gene [26]. IONIS-DMPK-2.5Rx is a chimeric antisense 
oligonucleotide and is currently under a randomized controlled study trail in DM1 
patients. Transthyretin amyloidosis is a form of systemic amyloidosis caused by 
misfolded transthyretin protein (TTR), in multiple tissues, including peripheral 
nerves, the gastrointestinal tract, and the heart [27]. Three different antisense 
drugs, IONIS-TTRRx, RNase H–dependent, and patisiran, are currently in develop-
ment for the treatment of TTR amyloidosis, as well as for both familial amyloid 
polyneuropathy and cardiomyopathy [28]. Spinal muscular atrophy (SMA), a 
progressive motor neuron disease, usually occurs in infancy or childhood caused 
by deletions or mutations in the survival of motor neuron 1 (SMN1) gene [29]. 
Nusinersen drug is a fully modified oligonucleotide designed to bind to a specific 
sequence in intron 7 of the SMN1 and 2 pre-mRNAs, enhancing exon 7 inclusion 
and increasing the production of SMN protein [30, 31] which is under review 
for market authorization. Huntington’s disease (HD) is an autosomal dominant 
neurodegenerative disorder resulting from an expanded CAG repeat in the hunting-
tin (HTT) gene, which causes a toxic gain of function due to an expanded polyglu-
tamine tract in the resulting protein. Antisense oligonucleotide designed to lower 
total HTT has been shown to provide a prolonged improvement in HD, and the drug 
is in clinical trial phase [30, 31].
3.5 Antisense therapy for infectious diseases
Various antisense mechanisms can be utilized to inhibit viral replication—for 
example, by binding to viral mRNA to block the translation of the protein or to 
degrade the viral RNA through an RNase mechanism or by blocking host microR-
NAs that support viral replication [6]. Several antisense therapies are currently 
undergoing clinical trials for various infectious diseases. MicroRNA-122 (miR-122) 
is highly abundant in the liver and is essential to the stability and propagation of 
hepatitis C virus (HCV) [32]. This mRNA binds to a highly conserved 5′ untrans-
lated region of the HCV genome, protecting it from degradation and host innate 
immune responses [32]. Additionally, miR-122 is also believed to play a major 
role in inflammatory activity in the liver [33], and RG-101, a GalNAc-conjugated 
oligonucleotide drug, is designed to inhibit miR-122 and HCV replication. The 
results from this clinical trial were very encouraging and support continued study 
of the drug.
4. The past, present, and future
The discovery of DNA as hereditary material and the helical structure base par-
ing of DNA have opened the new avenue toward the current understanding and use 
of nucleic acids for the development of oligonucleotide-based therapies [6, 34]. The 
antisense oligonucleotides bind to RNA through Watson-Crick base pairing theory 
and modulate the function of the targeted RNA. This leads to the key discovery and 
direct importance of development of oligonucleotide-based drugs and medicine [6, 
34]. The initial discovery of antisense technology is to enhance or improve the pro-
tein and small molecule-based technology by targeting RNA instead of protein. As 
a therapeutic strategy, it effects the RNA processing and modulates protein expres-
sion by binding to RNAs encoding difficult-to-target proteins. However, translating 
this technology into the clinic had some disadvantage such as inadequate target 
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arrangement, insufficient biological activity, and off-target toxic effects over two 
decades, but this strategy significantly develops the numbers and types of targets 
that can be approached for therapy. Further, this technology has a great advantage to 
develop drugs for the treatment of both monogenic and polygenic diseases as well as 
influence the human genetics and genomics [12, 34]. The novel chemical modifica-
tions of antisense oligonucleotides have been engaged to address these limitations 
over the years. Both antisense alterations and their mechanism of their action have 
not only improved the clinical trial design but also provide the breakthrough toward 
the translation of antisense oligonucleotide-based strategies into therapies [6, 34]. 
Additionally, multiple clinical trials have clearly confirmed the clinical uses of 
antisense pharmacology in humans and demonstrated their safety by using various 
mechanisms. The current antisense drugs, which are under clinical development 
phase, target different tissues both systemically and locally. The advanced oligo-
nucleotide chemistry further enhances the antisense drug properties by increasing 
potency, safety, and broader tissue distribution [6]. The advancement of oligonucle-
otide designs had improved the antisense mechanism of binding to RNA to inhibit 
their function with and without out RNA degradation. Recently, several researchers 
demonstrated that antisense oligonucleotides can also be utilized to overexpress 
or suppress the protein production [34, 35]. Many nonpathogenic disease condi-
tions lack an effective treatment; the rapid development of new improved next-
generation antisense oligonucleotide-based drugs bear the potential of intense 
clinical application and therapeutic impact on the treatment soon, demonstrating 
that this new class of molecular medicines/drugs has several potential and advan-
tageous applications in the clinic. There was always a lag period from the early 
discoveries till the therapy enters into the clinical trials and further in the market 
[34]. RNA-based precision medicine and gene therapy still need the improvement 
because of their off-target effects. The future applications of antisense technology 
will solely depend on the performance of novel molecules in the clinical trials. Till 
date tremendous progress has been made toward the antisense technology, despite 
the fact this has yet to deliver its full potential [36]. There are still more unanswered 
questions which need further improvement of the technology. The establishment 
of first-generation phosphorothioate oligodeoxynucleotides is a great asset and 
valuable pharmacological tool, which has shown the promise of new therapies to 
the patient. Further development of new improved second- and third-generation 
antisense oligonucleotides with novel formulation will result in better therapies 
for patients. Even though the tremendous progress has been made in antisense 
technology, there are still more questions that remain unanswered for the technol-
ogy and opportunities to further improve upon the platform [36]. This technology 
has provided solutions and confidence to diseases which were earlier considered 
untreatable. The high-cost factor has prevented this treatment mode inacces-
sible for the general masses. To fulfill the clinical need, future innovations to this 
technology might help in finding better and affordable cure to many more diseases 
which is available to all. Furthermore, the development of CRISPR, an RNA-guided 
gene-editing technology, and the delivery of mRNA transcribed in vitro are a major 
development of the RNA therapeutics. The clinical applications and validations of 
RNA-based antisense drugs for modulation of gene/protein expression and genome 
editing are currently being investigated both in the laboratory and in the clinic [1]. 
The CRISPR-Cas genome editing has transformed the field and impacted the bio-
medical science field which has stimulated the development of RNA-based antisense 
delivery approaches to facilitate clinical translation of CRISPR-Cas technology [1]. 
For cancer therapy, the first US-based human trial using CRISPR-Cas9 ex vivo is 
isolated from the T cells of cancer patients by knocking out the genes encoding 
PD1 and T-cell receptor alpha/beta [1]. Unquestionably, the field of antisense RNA 
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therapeutics is presently undertaking foremost development, and the potential for 
using RNA antisense drugs for personalized medicine and immunotherapy as well 
as to address genetic, infectious, and chronic diseases will ensure the continued 
development of antisense RNA therapeutics for years to come [1].
5. Summary and conclusion
In summary the antisense oligonucleotides are short, synthetic, single-stranded 
oligodeoxynucleotides that can alter RNA and reduce, restore, or modify protein 
expression through several distinct mechanisms by targeting the source of the 
pathogenesis; antisense-mediated therapies have a higher chance of success than 
therapies targeting downstream pathways. The advancement in the understanding 
of antisense pharmacology has provided new energy to translate these therapeutics 
into the clinic. Further advancement of antisense technology in the clinical settings 
requires more optimization of antisense delivery, target engagement, and safety 
profile. This technology holds the potential to change the therapeutic landscape for 
many disease conditions in near future. Most recently, the first gene therapy-based 
product, Gendicine (Ad-p53), got approved to treat head and neck squamous cell 
carcinoma in combination with radiotherapy. Also, the drug, Vitravene (known as 
fomivirsen), was approved for cytomegalovirus retinitis, Macugen (known as pegap-
tanib) for age-related macular degeneration, Kynamro (known as mipomersen) for 
homozygous familial hypercholesterolemia, Exondys 51 (known as eteplirsen) for 
Duchenne muscular dystrophy, Defitelio (known as defibrotide) for severe hepatic 
veno-occlusive disease, and Spinraza (known as nusinersen) for spinal muscular 
atrophy by the FDA. The development of antisense therapeutics has now become a 
clinical reality. The true advancement in the antisense design, chemistries, synthesis, 
and delivery technologies has been made for adequate stability, efficacy, specificity, 
and immune evasion. Finally, antisense technology is beginning to bear fruit.
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